BAGSVAERD, DENMARK--(Marketwire - September 28, 2009) - Novo Nordisk A/S - Share repurchase programme
On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.
Since the announcement as of 21 September 2009, the following transactions have been made under the programme:
Number Average Transaction of shares purchase price value, DKK Accumulated, last announcement 2,232,000 708,994,626 14 September 2009 75,000 326.7251 24,504,383 15 September 2009 70,000 329.8280 23,087,960 16 September 2009 85,000 324.1285 27,550,923 17 September 2009 150,500 315.6821 47,510,156 18 September 2009 70,000 317.1650 22,201,550 Accumulated under the programme 2,682,500 853,849,597
With the transactions stated above, Novo Nordisk owns a total of 27,519,308 treasury shares, corresponding to 4.4% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
Further information: Media: Investors: Outside North America: Outside North America: Mette Kruse Danielsen Mads Veggerby Lausten Tel: (+45) 4442 3883 Tel: (+45) 4443 7919 mkd@novonordisk.com mlau@novonordisk.com Kasper Roseeuw Poulsen Tel: 4442 4471 krop@novonordisk.com In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 57 / 2009
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
